Key result
Isoxazole 8 inhibits platelet aggregation by ~70% and reduces inflammatory markers sCD40L and sP-selectin.
Why the study?
Does synthetic isoxazole 8 inhibit platelet aggregation and reduce inflammatory marker expression in vitro?
Does synthetic isoxazole 8 inhibit platelet aggregation and reduce inflammatory marker expression in vitro?
Synthetic isoxazole 8 demonstrates significant in vitro antiplatelet activity and reduces inflammatory markers, suggesting potential as a novel antiplatelet agent.
Should not change practice; leaves open whether isoxazole 8 advances antiplatelet development beyond animal models.
Nine synthetic isoxazoles were evaluated as antiplatelet agents and studied the possible mechanism of more active compound. The initial screening was evaluating all compounds against platelet aggregation assays. The most active compound was isoxazole 8 showing an inhibition of platelet aggregation around 70%. In subsequent experiments, ADP and collagen were used as agonists to explore the possible inhibitory mechanisms of isoxazole 8 in platelet aggregation and secretion. We reported the effect of isoxazole 8 for reducing the expression of inflammatory markers, such as soluble CD40 ligand (sCD40L) and soluble P-selectin (sP-selectin), on activated platelets. Of this form, an inhibition of sCD40L and sP-selectin can prevent the onset of an atherosclerotic lesion.
No takes yet. Share an insight, caveat, or question.
Gutiérrez et al. (2013) studied Platelet aggregation. Isoxazole 8 was evaluated on Platelet aggregation inhibition. Isoxazole 8 inhibited platelet aggregation by approximately 70% and reduced the expression of inflammatory markers sCD40L and sP-selectin on activated platelets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: